Kenneth Galbraith - 15 Jan 2022 Form 4 Insider Report for Zymeworks Inc.

Reporting relationship: Chair, President & CEO, Director
Issuer ticker: N/A
Reported as of: 15 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jan 2022, 05:25:42 UTC
Prior SEC filing: 17 May 2021
Next SEC filing: 23 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Daniel Dex, Attorney-in-Fact

Key filing fact

Kenneth Galbraith filed Form 4 for Zymeworks Inc. on 18 Jan 2022.

Key facts

This page summarizes Kenneth Galbraith's Form 4 filing for Zymeworks Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jan 2022, 05:25.

Change

Previous filing in this sequence was filed on 17 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYME transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +500,000
Change %
Price: $0.000000
Shares after: 500,000
Date: 15 Jan 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 500,000
Exercise price: $14.97
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.